Argenx SE (NASDAQ:ARGX) on Thursday reported upbeat fourth-quarter results and announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).Argenx reported fourth-quarter earnings of $8.02 per share, beating the consensus of $6.02. Sales jumped from $761.2 million to $1.32 billion, surpassing the consensus estimate of $1.29 billion.“Argenx delivered another standout year of execution in 2025,” said Tim Van Hauwermeiren, CEO of Argenx ...

Amazon Web Services will be the exclusive third-party cloud distribution partner for OpenAI Frontier. ...

I'm a Ukraine-based seasoned investor, who firsthand experienced what’s it like to live in an environment full of systemic geopolitical shocks when the war came to my home country. Despite this, I managed to build an all-weather portfolio that has been able to thrive in volatile markets. My goal is to help investors find event-driven geopolitical ideas that can generate strong returns during periods of economic and political uncertainty.Analyst’s Disclosure: I/we have a beneficial long position in the share ...

As of Feb. 27, 2026, two stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according ...

Neils ChristensenNeils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada. He has worked exclusively within the financial sector since 2007, when he started with the Canadian Economic Press. Neils can be contacted at: 1 866 925 4826 ext. 1526 nchristensen at kitco.com @Neils_cShareDisclaimer: The views expressed ...

Key Takeaways US-Iran nuclear talks extended, keeping oil prices volatile and markets on edge.USO tracks daily crude moves, gaining 6% in a year amid headline-driven swings. ETFs like OIH show varied returns as energy equities react to shifting risk premiums.The latest round of U.S.-Iran nuclear talks concluded yesterday, leaving oil markets in a state of cautious stability after a period of intense pressure. During the Geneva discussions, Brent and WTI swung more than a dollar intraday as headlines flippe ...

Key Takeaways TFX Q4 adjusted EPS rose 1% to $1.93 but missed estimates by 48.3%, with revenues below consensus. Teleflex's gross margin fell 678 bps to 54% as costs jumped 51%, pressuring operating profit. TFX expects 2026 GAAP revenue growth of 14.4-15.4% and adjusted EPS of $6.25-$6.55. Teleflex Incorporated (TFX) posted fourth-quarter 2025 adjusted earnings per share (EPS) from continuing operations of $1.93, up 1% from the year-ago quarter’s figure. The metric missed the Zacks Consensus Estimate by 48. ...

Key Takeaways IONQ and QUBT are racing for quantum leadership with distinct trapped-ion and photonic tech. IONQ targets 2M qubits by 2030, posts 99.99% gate fidelity and 119.1% implied upside. QUBT secured NASA and NIST deals, a top U.S. bank sale and sees 107.4% upside. As the quantum computing industry continues its transition from a research frontier to real-world validation, different underlying technologies are emerging as potential winners. At one end of the spectrum is Quantum Computing Inc.’s (“QCi” ...

Lipocine (LPCN) shares soared 5.5% in the last trading session to close at $10. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.2% gain over the past four weeks.Lipocine’s stock price gain can be attributed to increasing investor confidence in recent pipeline developments of its investigational drug LPCN 1154 (oral brexanolone) for the treatment of postpartum depression. The company is evaluating the candidate in phase III stud ...

LAKE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Lakeland (LAKE) Investors of Securities Class Action Deadline on April 24, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses In Lakeland To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in [Lakeland](a) common stock pursuant and/or traceable to the registration statement and prospectus (collectively ...